EMEA: Clinical Investigation of Medicinal Products used in the Treatment of Osteoarthritis

This document is intended to provide guidance on the clinical evaluation of medicinal products in the treatment of osteoarthritis (OA). OA is a flaring degenerative arthropathy and a disorder ...

EMEA: Questions/answers on Endotoxin Testing and Sterility Testing at the end of shelf-life

Is endotoxin testing considered essential at the end of shelf life to confirm parenterals to be pyrogen-free? Is sterility testing considered essential at the end of shelf life to confirm ...

MHRA: Public consultation (MLX 358): The European Commission proposals on information to patients for prescription medicines

This consultation seeks your views on a European Commission proposal that would allow the pharmaceutical industry to provide information to the public on prescription only medicines (advertising ...

Ministry of Health: Regulation project concerning the changes in The Decree of Ministry of Health relating to the payment for Marketing Authorization of the medicinal products

The regulation project introduce the updated basic amount (from 1126 PLN to 1276 PLN). The payment for MA of the medicinal products is established in relation to the basic amount. ...

EMEA: Guideline on Missing data in confirmatory clinical trials

This guideline provides advice on how the presence of missing data in a confirmatory clinical trial should be addressed in a regulatory submission. ...

MHRA: Additional hypotensive effects following co-administration of non-selective alpha-blockers and phosphodiesterase-5-inhibitors: Guidance for marketing authorisation holders.

Requirement for marketing authorisation holders to submit Type II variations by 15 June 2009 to update licences with additional guidance on hypotensive effects. During the discussion of this ...

MHRA: Guidance on signposting from patient information leaflets

This guidance has been developed by the MHRA with advice from the Commission on Human Medicines Expert Advisory Group on Patient Information and in consultation with industry representatives. It ...

EMEA: Updated EMEA Post-Authorisation Procedural Advice Guidance

Human Medicines: Updated EMEA Post-Authorisation Procedural Advice Guidance - Questions & Answers - Type I Variations, Type II Variations, Reneval, PSURs and others. ...

EMEA: Updated pre-submission procedural guidance, for users of the centralised procedure

Human Medicines - EMEA Pre-Submission Procedural Advice - Questions & Answers ...

EMEA: Concept paper on the Development of a guideline on the use of Pharmacogenomics in the Pharmacokinetic Evaluation of medicinal products

A Reflection paper on the use of pharmacogenetics in the pharmacokinetic evaluation of medicinal products (EMEA/128517/2006) was published by the EMEA in May 2007. Since the drafting of this ...

kapitał ludzki

fundusz społeczny

Narodowe Centrum Badań i Rozwoju

innowacyjna gospodarka

rozwój regionalny